1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  
March 2018  
April 2018  
May 2018  
June 2018  
July 2018  
August 2018  
September 2018  
October 2018  
November 2018  
December 2018  
January 2019  
February 2019  
March 2019  
April 2019  
May 2019  
June 2019  
July 2019  
August 2019  
September 2019  
October 2019  
November 2019  
December 2019  
January 2020  
February 2020  
March 2020  
April 2020  
May 2020  
June 2020  
July 2020  
August 2020  
September 2020  
October 2020  
November 2020  
December 2020  
January 2021  
February 2021  
March 2021  
April 2021  
May 2021  
June 2021  
July 2021  
August 2021  
September 2021  
October 2021  
November 2021  
December 2021  
January 2022  
February 2022  
March 2022  
April 2022  
May 2022  
June 2022  
July 2022  
August 2022  
September 2022  
October 2022  
November 2022  
December 2022  
January 2023  
February 2023  
March 2023  
April 2023  
May 2023  
June 2023  
July 2023  
August 2023  
September 2023  
October 2023  
November 2023  
December 2023  
January 2024  
February 2024  
March 2024  

This page is powered by Blogger. Isn't yours?

Friday, March 17, 2017

 

Cancer Drug That Might Slow Parkinson's, Alzheimer's Headed For Bigger Tests

























A colored magnetic resonance imaging (MRI) scans of the brain of a 76-year-old patient with dementia shows the brain has atrophied and the dark brown fluid-filled spaces have become enlarged.
Zephyr/Science Source

Scientists are hoping that a single drug can treat two devastating brain diseases: Parkinson's and Alzheimer's.

The drug is nilotinib, which is approved to treat a form of leukemia.

In late 2015, researchers at Georgetown University Medical Center found that small doses of the drug appeared to help a handful of people with Parkinson's disease and a related form of dementia. They'd tried the unlikely treatment because they knew nilotinib triggered cells to get rid of faulty components — including the ones associated with several brain diseases.

Results of that preliminary study generated a lot of excitement because there is currently no treatment that can slow or halt the brain damage caused by either Parkinson's or Alzheimer's.

"Our phones were basically (ringing) off the hook," says Fernando Pagan, medical director of the translational neurotherapeutics program at Georgetown.

Many researchers were cautious, though. "It was such a small trial, there was no placebo control and it really wasn't designed to assess efficacy," says J. Paul Taylor, chair of the cell and molecular biology department at St. Jude Children's Research Hospital in Memphis.

So Georgetown is launching two larger and more rigorous trials of nilotinib, both designed with input from the Food and Drug Administration. One of the trials will enroll 75 patients with Parkinson's disease, the other will enroll 42 patients with Alzheimer's.

"This is going to help us identify what might have been a placebo effect and what is truly the effect of the medication," Pagan says.

Nilotinib seems to work by eliminating toxic proteins that build up in the brains of people with Parkinson's and Alzheimer's. The drug activates a mechanism in brain cells that acts like a sort of garbage disposal, Pagan says.

"Our drug goes into the cells to turn on that garbage disposal mechanism," Pagan says. "And if we're able to degrade these proteins, we could potentially stop the progression of this disorder."

The primary goal of the studies is to learn whether this powerful cancer drug is safe enough for patients with brain diseases. But the new studies should also provide better evidence about whether the drug really works.

That possibility attracts patients like Jonathan Lessin, a former anesthesiologist in the Washington D.C. area. Lessin was diagnosed with Parkinson's 14 years ago, when he was just 38.

Parkinson's gradually kills off brain cells that control movement. And for a decade after his diagnosis, drugs and a treatment called deep brain stimulation allowed Lessin to continue working. He retired several years ago, when his symptoms progressed to the point that he feared he might not be able to provide first-rate care for his patients.

Since then, the disease has caused Lessin's speech to become slightly slurred. "It's slowly progressing," he says. "My balance is getting worse and worse. I'm falling more and more during the day. But I'm still able to do things like rock climb and ski and bike."

Lessin has been able to stay active thanks to treatments that help control symptoms. But the disease continues to eat away areas of his brain.

So Lessin was excited to learn about the Georgetown study, which held the tantalizing prospect of a drug that just might slow or halt that process.

"I've always been riding the leading edge of treatment," Lessin says. "And I just figured I'd go for it."

As a former physician, Lessin fully understands the limitations of the earlier trial, and the risks of taking a powerful cancer drug. But as someone with Parkinson's, he sees an opportunity.

"I'm very optimistic," he says. "I've seen it cure Parkinson's in mice. I've seen people who can talk again, walk again, which is very encouraging."

There's good reason for patients with Parkinson's, Alzheimer's and other neurodegenerative diseases to be optimistic these days, Taylor says.

Drugs like nilotinib are coming along because years of research have provided a much better understanding of how these damage the brain, he says. "Now we're in the payoff phase."

Taylor still isn't sure whether nilotinib will live up to its early promise. But, he says, "If the results of this trial don't turn out to be as exciting as the very tiny trial suggested, I would not get too pessimistic because there are other developments that are in the wings."

The Georgetown studies are enrolling patients now and will take more than a year to complete.

Story Source: The above story is based on materials provided by NPR
Note: Materials may be edited for content and length